Therefore, the current definition of HER2 positivity in BC may neither fully reflect the spectrum of oncogenic activity of HER2 signalling pathways that drive BC growth, differentiation and behaviour nor the clinical and biological heterogeneity within these tumours. The gene discussed is ERBB2; the disease is neoplasm.